Professional Documents
Culture Documents
CRITICAL APPRAISAL
Disusun oleh :
Dosen Pembimbing :
dr. Hj. Isna Indrawati MSc
PERTANYAAN KLINIS:
Apakah terapi kombinasi deferoxamine dan deferiprone lebih efektif dibandingkan terapi
deferoxamine saja?
KOMPONEN PICO:
Patient /Population/Problem : anak laki-laki 12 tahun yang akan melakukan transfusi
darah
Intervention/ Indicator : terapi kombinasi deferoxamine dan deferiprone
Comparison/Control : terapi dengan deferoxamine
Objective/Outcome : kombinasi deferoxamine dan deferiprone lebih efektif
untuk mencegah hemosiderosis
KATA KUNCI:
Thalassemia AND deferoxamine AND deferiprone
PEMILIHAN SITUS:
http://www.ebscohost.com
LIMITASI :
5 tahun terakhir
HASIL PENCARIAN :
48
1
REVIEW JURNAL
Objective:
To determine the effect of combined therapy with deferoxamine and deferiprone on serum
ferritin level of beta-thalassemic patients.
Results:
The mean of serum ferritin level in case group significantly decreased from 7539.8 3434.9 g/l
at
the beginning of study to 4848.7 2706.2 g/l (P < 0.001) and to 4338.3 2308.8 g/l (P
<0.001) at the end of the third and the sixth months of study, respectively. The mean of serum
ferritin level in control group insignificantly increased from 5668 3613.8 to 6210.8 3940.9
g/l and to 5742 3205.9 g/l at the end of the third and the sixth months of study, respectively.
The common side effects of combined therapy were nausea (8.3%) and arthropathy (8.3%). A
mild transient neutropenia and liver enzymes elevation happened in four patients of case group.
Conclusion:
Combined therapy with deferoxamine and deferiprone significantly decreases serum ferritin
level. It has little side effect and is suggested for major beta-thalassemic patients as a suitable
therapy.
2
TELAAH KRITIS ARTIKEL TERAPI
I. VALIDITY
1. Menentukan ada atau tidaknya randomisasi dalam kelompok dan teknik
randomisasi yang digunakan
Ada, dijelaskan pada methods and materials dan teknik randomisasi yang
digunakan adalah controlled clinical trial.
Ada, pasien dalam jurnal ini berada pada kondisi yang sama pada
kelompok kasus dan kelompok kontrol sebelum dilakukan penelitian.
3
3. Menentukan ada tidaknya blinding pada pasien, klinisi dan peneliti
4
II. IMPORTANCE
7. Menentukan besar efek terapi (EER, CER, RR, RRR, ARR, NNT)
III. APPLICABILITY
5
10. Menentukan potensi keuntungan dan kerugian bagi pasien